Last reviewed · How we verify
NCT06814873
Enhanced Human Sensorimotor Integration Via Self-modulation of the Somatosensory Activity
NA trial testing Neurofeedback in Somatosensory Evoked Potentials, and Electroencephalography in 39 participants. Completed in 31 March 2024.
31 March 2024
Quick facts
| Lead sponsor | Keio University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 39 |
| Start date | 10 May 2023 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Neurofeedback
- Sham-feedback
Conditions studied
- Somatosensory Evoked Potentials, and Electroencephalography — all drugs for Somatosensory Evoked Potentials, and Electroencephalography →
Sponsor
Keio University
Who can join
18 and older, any sex, with Somatosensory Evoked Potentials, and Electroencephalography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the functional and structural modification effects on the brain of a non-invasive experimental device applied to the head and forearms of healthy subjects during motor recall training. The experimental device used in this study is the Brain-Machine Interface (hereinafter referred to as BMI), which is under development in the principal investigator's laboratory. The BMI consists of an arithmetic unit that processes the results in real time using a personal computer, a depth ray that displays the results, a transcutaneous electrical stimulator that is driven based on the results of the arithmetic, and an exoskeletal motor assist device that is driven based on the results of the arithmetic.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Enhanced human sensorimotor integration via self-modulation of the somatosensory activity.
Iwama S, Ueno T, Fujimaki T, Ushiba J. · · 2025 · PMID 40151645 · DOI 10.1016/j.isci.2025.112145
Verify or expand the search:
- PubMed search for NCT06814873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neurofeedback
Trials testing the same drug.
- NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
- NCT06587919 — Improving Dysregulated Neural Networks With EEG-neurofeedback · NA · enrolling by invitation
- NCT06240299 — Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) · NA · recruiting
- NCT06188910 — Neurofeedback and Nomophobia in Young Adults · NA · completed
- NCT06557525 — Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER) · Phase 1, PHASE2 · recruiting
Other Keio University trials
Trials by the same sponsor.
- NCT06913907 — Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study) · Phase 4 · recruiting
- NCT04546074 — Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma · Phase 1, PHASE2 · unknown
- NCT04699994 — Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel · Phase 2 · unknown
- NCT03505008 — Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06814873 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Keio University
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing